|
1
|
Acharya SK: Epidemiology of hepatocellular
carcinoma in India. J Clin Exp Hepatol. 4 Suppl 3:S27–S33. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertagna F, Bertoli M, Bosio G, Biasiotto
G, Sadeghi R, Giubbini R and Treglia G: Diagnostic role of
radiolabelled choline PET or PET/CT in hepatocellular carcinoma: A
systematic review and meta-analysis. Hepatol Int. 8:493–500. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guan Q, Gu J, Zhang H, Ren W, Ji W and Fan
Y: Correlation between vascular endothelial growth factor levels
and prognosis of hepatocellular carcinoma patients receiving
radiofrequency ablation. Biotechnol Biotechnol Equip. 29:119–123.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hefaiedh R, Sabbegh M, Ennaifer R,
Romdhane H, Ben Nejma H, Belhadj N, Gharbi L and Khalfallah T:
Percutaneous treatment versus hepatic resection for the treatment
of small hepatocellular carcinoma. Tunis Med. 92:711–716.
2014.PubMed/NCBI
|
|
5
|
Mansourian PG, Yoneda M, Rao M Krishna,
Martinez FJ, Thomas E and Schiff ER: Effects of statins on the risk
of hepatocellular carcinoma. Gastroenterol Hepatol (N Y).
10:417–426. 2014.PubMed/NCBI
|
|
6
|
Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu
TP, Yin L, Zhang EB, De W and Shu YQ: Long non-coding RNA ANRIL is
upregulated in hepatocellular carcinoma and regulates cell
apoptosis by epigenetic silencing of KLF2. J Hematol Oncol.
8:502015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu WH, Zhang JB, Dang Z, Li X, Zhou T, Liu
J, Wang DS, Song WJ and Dou KF: Long non-coding RNA URHC regulates
cell proliferation and apoptosis via ZAK through the ERK/MAPK
signaling pathway in hepatocellular carcinoma. Int J Biol Sci.
10:664–676. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tu ZQ, Li RJ, Mei JZ and Li XH:
Down-regulation of long non-coding RNA GAS5 is associated with the
prognosis of hepatocellular carcinoma. Int J Clin Exp Pathol.
7:4303–4309. 2014.PubMed/NCBI
|
|
10
|
Chen CL, Tseng YW, Wu JC, Chen GY, Lin KC,
Hwang SM and Hu YC: Suppression of hepatocellular carcinoma by
baculovirus-mediated expression of long non-coding RNA PTENP1 and
MicroRNA regulation. Biomaterials. 44:71–81. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ
and Ma WL: High expression of long non-coding RNA ANRIL is
associated with poor prognosis in hepatocellular carcinoma. Int J
Clin Exp Pathol. 8:3076–3082. 2015.PubMed/NCBI
|
|
12
|
Shi XM and Teng F: Up-regulation of long
non-coding RNA Sox2ot promotes hepatocellular carcinoma cell
metastasis and correlates with poor prognosis. Int J Clin Exp
Pathol. 8:4008–4014. 2015.PubMed/NCBI
|
|
13
|
Cao Y, Lindström S, Schumacher F, Stevens
VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F,
Chamosa S, et al: Insulin-like growth factor pathway genetic
polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer
survival. J Natl Cancer Inst. 106:dju0852014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vu TH, Chuyen NV, Li T and Hoffman AR:
Loss of imprinting of IGF2 sense and antisense transcripts in
Wilms' tumor. Cancer Res. 63:1900–1905. 2003.PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malik R, Patel L, Prensner JR, Shi Y, Iyer
MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, et al: The
lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol
Cancer Res. 12:1081–1087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng
R, Wang Y, Huang J, Xu M, Yan J and Yu J: lncRNA H19/miR-675 axis
represses prostate cancer metastasis by targeting TGFBI. FEBS J.
281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L,
Zhang X, Sun W, Song H, Xiao B and Guo J: lncRNA-AC130710 targeting
by miR-129-5p is upregulated in gastric cancer and associates with
poor prognosis. Tumour Biol. 35:9701–9706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Endo H, Shiroki T, Nakagawa T, Yokoyama M,
Tamai K, Yamanami H, Fujiya T, Sato I, Yamaguchi K, Tanaka N, et
al: Enhanced expression of long non-coding RNA HOTAIR is associated
with the development of gastric cancer. PLoS One. 8:e770702013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng HT, Shi DB, Wang YW, Li XX, Xu Y,
Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA
MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Int J Clin Exp Pathol. 7:3174–3181. 2014.PubMed/NCBI
|
|
21
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Lu N, Niu B, Chen X, Xie J and
Cheng N: Overexpression of Aurora-A enhances invasion and matrix
metalloproteinase-2 expression in esophageal squamous cell
carcinoma cells. Mol Cancer Res. 10:588–596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kinkade CW, Castillo-Martin M, Puzio-Kuter
A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL,
Cordon-Cardo C and Abate-Shen C: Targeting AKT/mTOR and ERK MAPK
signaling inhibits hormone-refractory prostate cancer in a
preclinical mouse model. J Clin Invest. 118:3051–3064.
2008.PubMed/NCBI
|
|
24
|
Moro L, Arbini AA, Marra E and Greco M:
Constitutive activation of MAPK/ERK inhibits prostate cancer cell
proliferation through upregulation of BRCA2. Int J Oncol.
30:217–224. 2007.PubMed/NCBI
|
|
25
|
Mebratu Y and Tesfaigzi Y: How ERK1/2
activation controls cell proliferation and cell death: Is
subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
View Article : Google Scholar : PubMed/NCBI
|
